ABSTRACT
Since 1975 when King and Mills introduced the first prototype percutaneous atrial septal defect (ASD) device more than 20 devices have been developed with few of them reaching the stage of clinical usage. Over the last few decades, ASD devices have become lighter and smaller, making percutaneous closure methods easier and safer, almost replacing surgical closure even in complex subset of ASD defects which were initially attempted closure with surgical methods. Promising developments such as wireless bioresorbable devices can reduce complications related to hardware and if successful may provide breakthrough in the development of percutaneous ASD devices in the future.
